Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Netherlands Heart Journal
Published in: Netherlands Heart Journal 9/2009

01-09-2009 | Interuniversity Cardiology Institute of the Netherlands

Cardiac resynchronisation therapy and the role of optimal device utilisation

Authors: S. Buck, A. H. Maass, D. J. van Veldhuisen, I. C. Van Gelder

Published in: Netherlands Heart Journal | Issue 9/2009

Login to get access

Abstract

Despite established selection criteria, 30 to 40% of patients do not respond to cardiac resynchronisation therapy. By optimising programming of the device response to cardiac resynchronisation, therapy can be improved. (Neth Heart J 2009;17:354–7.)
Literature
1.
Manolis AS. Cardiac resynchronization therapy in congestive heart failure: Ready for prime time? Heart Rhythm. 2004;1:355–63.
2.
Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–50.
3.
Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.
4.
Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10:933–89.
5.
Ypenburg C, van Bommel RJ, Delgado V, Mollema SA, Bleeker GB, Boersma E, et al. Optimal left ventricular lead position predicts reverse remodeling and survival after cardiac resynchronization therapy. J Am Coll Cardiol. 2008;52:1402–9.
6.
Buck S, Maass AH, Nieuwland W, Anthonio RL, van Veldhuisen DJ, Van Gelder IC. Impact of interventricular lead distance and the decrease in septal-to-lateral delay on response to cardiac resynchronization therapy. Europace. 2008;10:1313–9.
7.
Mair H, Sachweh J, Meuris B, Nollert G, Schmoeckel M, Schuetz A, et al. Surgical epicardial left ventricular lead versus coronary sinus lead placement in biventricular pacing. Eur J Cardiothorac Surg. 2005;27:235–42.
8.
Sawhney NS, Waggoner AD, Garhwal S, Chawla MK, Osborn J, Faddis MN. Randomized prospective trial of atrioventricular delay programming for cardiac resynchronization therapy. Heart Rhythm. 2004;1:562–7.
9.
Maass AH, Buck S, Nieuwland W, Brügemann J, van Veldhuisen DJ, Van Gelder IC. Importance of Heart Rate During Exercise for Response to Cardiac Resynchronization Therapy. J Cardiovasc Electrophysiol. 2009.
10.
Gasparini M, Auricchio A, Metra M, Regoli F, Fantoni C, Lamp B, et al. Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J. 2008;29:1644–52.
11.
Khadjooi K, Foley PW, Chalil S, Anthony J, Smith RE, Frenneaux MP, et al. Long-term effects of cardiac resynchronisation therapy in patients with atrial fibrillation. Heart. 2008;94:879–83.
12.
Buck S, Rienstra M, Maass AH, Nieuwland W, van Veldhuisen DJ, van Gelder IC. Cardiac resynchronization therapy in patients with heart failure and atrial fibrillation: importance of new-onset atrial fibrillation and total atrial conduction time. Europace. 2008;10:558–65.
13.
Borleffs CJ, Ypenburg C, van Bommel RJ, Delgado V, van Erven L, Schalij MJ, et al. Clinical importance of new-onset atrial fibrillation after cardiac resynchronization therapy. Heart Rhythm. 2009;6:305–10.
14.
Ellery S, Pakrashi T, Paul V, Sack S. Predicting mortality and rehospitalization in heart failure patients with home monitoring—the Home CARE pilot study 1. Clin Res Cardiol. 2006;95 Suppl 3:III29–III35.
15.
Ricci RP, Morichelli L, Santini M. Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation. Europace. 2009;11:54–61.
Metadata
Title
Cardiac resynchronisation therapy and the role of optimal device utilisation
Authors
S. Buck
A. H. Maass
D. J. van Veldhuisen
I. C. Van Gelder
Publication date
01-09-2009
Publisher
Bohn Stafleu van Loghum
Published in
Netherlands Heart Journal / Issue 9/2009
Print ISSN: 1568-5888
Electronic ISSN: 1876-6250
DOI
https://doi.org/10.1007/BF03086283

Other articles of this Issue 9/2009

Netherlands Heart Journal 9/2009 Go to the issue

Original article

Long-term efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension

Review article

Cardiopulmonary exercise testing in congenital heart disease: equipment and test protocols

Study design article

RESPONSE study: Randomised Evaluation of Secondary Prevention by Outpatient Nurse SpEcialists

Original article

Bosentan in pulmonary arterial hypertension: a comparison between congenital heart disease and chronic pulmonary embolism

Editor's page

From concept to product in cardiology

Imaging in cardiology

Non-bacterial thrombotic endocarditis in metastatic caecal adenocarcinoma

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits